AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23522182 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1656 (20-140 mg)
Number of subjects: 224
Study 23522182 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1656 (10-80 mg)
Number of subjects: 224
Study 23522182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 21346213 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS
Number of subjects: 10
Study 21346213 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS(25)
Number of subjects: 10
Study 21346213 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hz rTMS
Number of subjects: 10
Study 21346213 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS(10)
Number of subjects: 10
Study 21346213 — intervention group
Group type: EXPERIMENTAL
Intervention: cTBS
Number of subjects: 10
Study 21346213 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS
Number of subjects: 10
Study 21346213 — intervention group
Group type: COMPARATOR
Intervention: Contralateral hemisphere
Number of subjects: 10
Study 19475523 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided exercise programme
Number of subjects: 42
Study 19475523 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 42
Study 17826067 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction intraoperative radiotherapy (IORT) prescribed at 20 Gy to the surgical margins using soft x-rays (50 kV) delivered with the Intrabeam Photon Radiosurgery System.
Number of subjects: 779
Study 17826067 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation postoperatively.
Number of subjects: 779
Study 11035612 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) once daily (400 mg/day, 250 mg/day if body weight <60 kg)
Number of subjects: 121
Study 11035612 — intervention group
Group type: COMPARATOR
Intervention: Didanosine (ddI) twice daily (400 mg/day, 250 mg/day if body weight <60 kg)
Number of subjects: 121
Study 11035612 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) once daily and twice daily
Number of subjects: 121
Study 8840065 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve stimulator technique (NS)
Number of subjects: 46
Study 8840065 — intervention group
Group type: COMPARATOR
Intervention: Loss of resistance technique (LOR)
Number of subjects: 46
Study 1353489 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast preservation
Number of subjects: 1036
Study 1353489 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 1036
Study 1353489 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast preservation with microscopically involved margins
Number of subjects: 1036
Study 1353489 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall local recurrences
Number of subjects: 1036
Study 1353489 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall regional recurrences
Number of subjects: 1036
Study 1353489 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall distant metastases
Number of subjects: 1036
Study 1353489 — intervention group
Group type: EXPERIMENTAL
Intervention: P-185 expression
Number of subjects: 1036
Study 6496450 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms doses of heat-inactivated hepatitis B surface antigen (HBsAg) at one-month intervals (trial A)
Number of subjects: 471
Study 6496450 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 different dosages of the vaccine (trial B)
Number of subjects: 471
Study 30215690 — intervention group
Group type: EXPERIMENTAL
Intervention: Teprotumumab, a monoclonal inhibitory antibody targeting IGF‐IR
Number of subjects: 0
Study 29606129 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Steps-Drug Use (LS-DU) intervention
Number of subjects: 0
Study 29606129 — intervention group
Group type: COMPARATOR
Intervention: Health education intervention (control)
Number of subjects: 0
Study 27749351 — intervention group
Group type: EXPERIMENTAL
Intervention: cFNB
Number of subjects: 120
Study 27749351 — intervention group
Group type: EXPERIMENTAL
Intervention: sFNB
Number of subjects: 120
Study 27749351 — intervention group
Group type: EXPERIMENTAL
Intervention: LIA
Number of subjects: 120
Study 22614110 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year gluten-free diet
Number of subjects: 222
Study 20530110 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN with heparin (0.5 IU/ml)
Number of subjects: 210
Study 20530110 — intervention group
Group type: COMPARATOR
Intervention: TPN without heparin
Number of subjects: 210
Study 18842911 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids treatment based on eNO and sEos levels
Number of subjects: 14
Study 18842911 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment based on symptoms and function
Number of subjects: 14
Study 16080456 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected anal intercourse (UAI) reported in 1999
Number of subjects: 0
Study 16080456 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected anal intercourse (UAI) reported in 2002
Number of subjects: 0
Study 16080456 — intervention group
Group type: EXPERIMENTAL
Intervention: Jackson Heights community
Number of subjects: 0
Study 16080456 — intervention group
Group type: EXPERIMENTAL
Intervention: San Gabriel Valley community
Number of subjects: 0
Study 16080456 — intervention group
Group type: EXPERIMENTAL
Intervention: Detroit community
Number of subjects: 0
Study 16080456 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Cities community
Number of subjects: 0
Study 16080456 — intervention group
Group type: COMPARATOR
Intervention: Atlanta community
Number of subjects: 0
Study 16080456 — intervention group
Group type: COMPARATOR
Intervention: San Diego community
Number of subjects: 0
Study 15458106 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic feedback during suturing simulation
Number of subjects: 0
Study 7723340 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 200 mg intravenously 1 hour preoperatively
Number of subjects: 33
Study 7723340 — intervention group
Group type: COMPARATOR
Intervention: Control (no allopurinol)
Number of subjects: 33
Study 2383382 — intervention group
Group type: EXPERIMENTAL
Intervention: Range of motion by the therapist
Number of subjects: 48
Study 2383382 — intervention group
Group type: EXPERIMENTAL
Intervention: Skate board
Number of subjects: 48
Study 2383382 — intervention group
Group type: EXPERIMENTAL
Intervention: Overhead pulley
Number of subjects: 48
Study 30882237 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal own milk (MOM) stimulation
Number of subjects: 36
Study 30882237 — intervention group
Group type: COMPARATOR
Intervention: Water (sham) stimulus
Number of subjects: 36
Study 28110424 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine group (n = 15), coffee containing 222 mg of caffeine 2 hours before catheterization
Number of subjects: 30
Study 28110424 — intervention group
Group type: COMPARATOR
Intervention: Non-caffeine group (n = 15), instructed not to take caffeine for at least 12 hours before catheterization
Number of subjects: 30
Study 28110424 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine group (n = 15)
Number of subjects: 30
Study 28110424 — intervention group
Group type: COMPARATOR
Intervention: Non-caffeine group (n = 15)
Number of subjects: 30
Study 27273884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle Ergometry (CE) with 10 g protein/46 g carbohydrate drink (223 kcal)
Number of subjects: 113
Study 27273884 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat rations supplemented with 1000 kcal/day from 20 g protein- or 48 g carbohydrate-based bars
Number of subjects: 113
Study 27273884 — intervention group
Group type: COMPARATOR
Intervention: Combat rations alone (control)
Number of subjects: 113
Study 27273884 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy balance during military training
Number of subjects: 113
Study 24518871 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual increase in ambient temperature (+4 K/h, ranging from 24 °C to 32 °C)
Number of subjects: 16
Study 24518871 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual decrease in ambient temperature (‐4 K/h, ranging from 24 °C to 16 °C)
Number of subjects: 16
Study 21173703 — intervention group
Group type: EXPERIMENTAL
Intervention: Static accommodation
Number of subjects: 33
Study 21173703 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated accommodation
Number of subjects: 33
Study 21173703 — intervention group
Group type: COMPARATOR
Intervention: Comparison of static vs repeated accommodation
Number of subjects: 33
Study 20345030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-point spin reduction of spinal manipulation therapy
Number of subjects: 168
Study 20345030 — intervention group
Group type: COMPARATOR
Intervention: Dialectical prescription
Number of subjects: 168
Study 18631903 — intervention group
Group type: EXPERIMENTAL
Intervention: MPT-OA plus standard treatment
Number of subjects: 21
Study 18631903 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 21
Study 15993403 — intervention group
Group type: EXPERIMENTAL
Intervention: Illiterate individuals
Number of subjects: 0
Study 15993403 — intervention group
Group type: COMPARATOR
Intervention: Literate individuals
Number of subjects: 0
Study 12362781 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-encapsulated ferrous fumarate (12.5 mg of elemental iron)
Number of subjects: 39
Study 10355573 — intervention group
Group type: EXPERIMENTAL
Intervention: Further chemotherapy (3 courses of MIP: cisplatin 50 mg/m2, ifosfamide 3 g/m2, mitomycin C 6 mg/m2)
Number of subjects: 115
Study 10355573 — intervention group
Group type: COMPARATOR
Intervention: Chest irradiation (60 Gy; 2 Gy per fraction over six weeks)
Number of subjects: 115
Study 10355573 — intervention group
Group type: COMPARATOR
Intervention: Chest irradiation
Number of subjects: 115
Study 7732981 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nicardipine
Number of subjects: 53
Study 7732981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 7732981 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label nicardipine (30 or 40 mg three times a day for 1 week)
Number of subjects: 53
Study 7732981 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 53
Study 1975199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole 100 mg i.v.
Number of subjects: 6
Study 1975199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole 30 mg i.v.
Number of subjects: 6
Study 1975199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole 10 mg i.v.
Number of subjects: 6
Study 1975199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole (oral dosing)
Number of subjects: 6
Study 1975199 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study 7298122 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention program to modify the family diet toward a goal of 70 mEq sodium per person per day.
Number of subjects: 80
Study 7298122 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention).
Number of subjects: 80
Study 31385637 — intervention group
Group type: EXPERIMENTAL
Intervention: Slice GRAPPA
Number of subjects: 0
Study 31385637 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-slice GRAPPA
Number of subjects: 0
Study 31385637 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative acquisition with varied slice pairings
Number of subjects: 0
Study 28052840 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based complaint-directed mini-interventions (CDMIs)
Number of subjects: 329
Study 28052840 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 329
Study 25709097 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ(9)‐THC 0.03 mg/kg
Number of subjects: 20
Study 25709097 — intervention group
Group type: COMPARATOR
Intervention: Δ(9)‐THC 0.015 mg/kg
Number of subjects: 20
Study 25709097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24112372 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep disturbances
Number of subjects: 249
Study 21406672 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitors plus nurse-delivered, telephone-based tailored patient education intervention (n=150)
Number of subjects: 450
Study 21406672 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitors plus Web-based tailored patient education intervention (n=150)
Number of subjects: 450
Study 21406672 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=150)
Number of subjects: 450
Study 21406672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention groups (n=150 each)
Number of subjects: 450
Study 19966651 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-gauge needle
Number of subjects: 30
Study 19966651 — intervention group
Group type: COMPARATOR
Intervention: 30-gauge needle
Number of subjects: 30
Study 17484218 — intervention group
Group type: EXPERIMENTAL
Intervention: Live pentavalent rotavirus vaccine (PRV)
Number of subjects: 1358
Study 17484218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1358
Study 15754631 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (1.5 mg/m2 daily for 5 days, repeated 5 times with 21-day intervals)
Number of subjects: 35
Study 15754631 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 35
Study 15754631 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan
Number of subjects: 35
Study 11586196 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic skills training (30 minutes daily for 10 days)
Number of subjects: 12
Study 11586196 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 12
Study 11586196 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic skills training
Number of subjects: 12
Study 9704732 — intervention group
Group type: EXPERIMENTAL
Intervention: VACOP-B for 12 weeks
Number of subjects: 124
Study 9704732 — intervention group
Group type: EXPERIMENTAL
Intervention: VACOP-B for 12 weeks plus high-dose therapy (HDT) and autologous bone marrow transplantation (ABMT)
Number of subjects: 124
Study 9704732 — intervention group
Group type: COMPARATOR
Intervention: VACOP-B for 12 weeks plus HDT and ABMT
Number of subjects: 124
Study 7988262 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative mitomycin, vinblastine, and cisplatin (MVP) chemotherapy (cisplatin 120 mg/m2, mitomycin 8 mg/m2 on day 1 + 29, vinblastine 4.5 mg/m2 on days 1, 15, 22, and 29, and 2.0 mg/m2 on day 8)
Number of subjects: 67
Study 7988262 — intervention group
Group type: COMPARATOR
Intervention: Preoperative radiotherapy (44 Gy in 22 fractions to the primary tumor and mediastinum)
Number of subjects: 67
Study 7988262 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 67
Study 7988262 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall toxicity
Number of subjects: 67
Study 2498414 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA (recombinant tissue plasminogen activator)
Number of subjects: 115
Study 2498414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 31923105 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tACS (20 daily 40-min sessions at 77.5 Hz, 15 mA)
Number of subjects: 92
Study 31923105 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS (placebo control)
Number of subjects: 92
Study 31634198 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir disoproxil fumarate (TDF) for pre‐exposure prophylaxis (PrEP)
Number of subjects: 33
Study 31634198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 28665071 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) at 34.5°C for 48 hours followed by 48 hours of slow rewarming
Number of subjects: 22
Study 28665071 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 22
Study 28665071 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 26231324 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for lowering PO4
Number of subjects: 36
Study 26231324 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching about dietary and medication adherence
Number of subjects: 36
Study 26231324 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study 23057646 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra care aide (CA) support
Number of subjects: 20
Study 23057646 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal alarms (PA)
Number of subjects: 20
Study 23057646 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 20
Study 21529365 — intervention group
Group type: EXPERIMENTAL
Intervention: mRDT implementation in intervention health facilities
Number of subjects: 0
Study 21529365 — intervention group
Group type: COMPARATOR
Intervention: Control health facilities without mRDTs
Number of subjects: 0
Study 20218321 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianliean Suppository (1 pill per night for 28 days)
Number of subjects: 467
Study 20218321 — intervention group
Group type: COMPARATOR
Intervention: Yejuhua Suppository (1 pill per night for 28 days)
Number of subjects: 467
Study 20218321 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianliean Suppository
Number of subjects: 467
Study 20218321 — intervention group
Group type: COMPARATOR
Intervention: Yejuhua Suppository
Number of subjects: 467
Study 17020067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilated nasal packs
Number of subjects: 0
Study 17020067 — intervention group
Group type: COMPARATOR
Intervention: Non-ventilated (glove-finger) nasal packs
Number of subjects: 0
Study 15190137 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation
Number of subjects: 221
Study 15190137 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 221
Study 11679529 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Number of subjects: 186
Study 11679529 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingectomy in patients with ultrasound-visible hydrosalpinges
Number of subjects: 186
Study 11679529 — intervention group
Group type: COMPARATOR
Intervention: No surgical intervention (control group)
Number of subjects: 186
Study 10205311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of 50% medium‐chain triglycerides and 50% long-chain triglycerides
Number of subjects: 20
Study 10205311 — intervention group
Group type: COMPARATOR
Intervention: 100% long-chain triglycerides
Number of subjects: 20
Study 7827351 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic children
Number of subjects: 129
Study 3124680 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT), 200 or 250 mg every 4 hours
Number of subjects: 16
Study 3124680 — intervention group
Group type: COMPARATOR
Intervention: Other regimens
Number of subjects: 16
Study 3124680 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring antigenemia
Number of subjects: 16
Study 29077181 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable suture recession
Number of subjects: 40
Study 29077181 — intervention group
Group type: COMPARATOR
Intervention: Nonadjustable suture recession
Number of subjects: 40
Study 26999045 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated central venous catheters (CVCs)
Number of subjects: 8831
Study 26999045 — intervention group
Group type: COMPARATOR
Intervention: Standard central venous catheters (CVCs)
Number of subjects: 8831
Study 26226067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Ji Quan
Number of subjects: 0
Study 26226067 — intervention group
Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 0
Study 26226067 — intervention group
Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 0
Study 23442608 — intervention group
Group type: EXPERIMENTAL
Intervention: DTwP-Local
Number of subjects: 672
Study 23442608 — intervention group
Group type: COMPARATOR
Intervention: DTwP-Pasteur
Number of subjects: 672
Study 22162648 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 14
Study 22162648 — intervention group
Group type: COMPARATOR
Intervention: Wellness Education (WE)
Number of subjects: 14
Study 17851757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib 300 mg (TL)
Number of subjects: 120
Study 17851757 — intervention group
Group type: COMPARATOR
Intervention: Placebo (L)
Number of subjects: 120
Study 17146314 — intervention group
Group type: EXPERIMENTAL
Intervention: Energizers (classroom-based physical activity program)
Number of subjects: 243
Study 12749480 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 0
Study 10633513 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% nitrous oxide/60% oxygen inhalation
Number of subjects: 22
Study 10633513 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen inhalation
Number of subjects: 22
Study 8602667 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg x kg(-1) edrophonium
Number of subjects: 100
Study 8602667 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 100
Study 2368149 — intervention group
Group type: EXPERIMENTAL
Intervention: Double therapy (cyclosporine and steroids)
Number of subjects: 209
Study 2368149 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (cyclosporine in lower initial dose, azathioprine, and steroids)
Number of subjects: 209
Study 99235 — intervention group
Group type: EXPERIMENTAL
Intervention: IV hyperalimentation (IVH) administered before and after the first course of CIA for a total of 31 days
Number of subjects: 26
Study 99235 — intervention group
Group type: EXPERIMENTAL
Intervention: IV hyperalimentation (IVH)
Number of subjects: 26
Study 99235 — intervention group
Group type: COMPARATOR
Intervention: CIA chemoimmunotherapy
Number of subjects: 26
Study 30646862 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28464887 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT Condition with face-to-face, tailored counseling focusing on child's illness, reducing child SHSe, caregiver smoking cessation, and nicotine replacement therapy option.
Number of subjects: 0